Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-pulsed dendritic cell vaccine (University of Michigan)
- Development stage
- Discontinued
- Lead developer
- University of Michigan Rogel Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
The autologous tumor-pulsed dendritic cell vaccine developed by the University of Michigan Rogel Cancer Center is an individualized cellular immunotherapy investigated for the treatment of metastatic colorectal cancer. The therapeutic process involves harvesting a patient's own dendritic cells (DCs) from peripheral blood, which are then matured ex vivo and pulsed with antigens derived from the patient's own autologous tumor lysate. Upon re-administration, these dendritic cells act as professional antigen-presenting cells to prime and activate the patient's T cells against tumor-specific antigens. In clinical trial contexts (such as NCT00004149), this vaccine was administered in combination with subcutaneous Interleukin-2 (IL-2) to further stimulate the expansion and effector function of the induced tumor-reactive cytotoxic T lymphocytes.
- Other names
- Autologous Tumor-Pulsed Dendritic Cell Vaccine with IL-2DC/Tumor Lysate VaccineAutologous Tumor-Pulsed Dendritic Cell Vaccine-University of Michigan Rogel Cancer Center-colorectal cancer
Beyond the preview
Go deeper on autologous tumor-pulsed dendritic cell vaccine (University of Michigan).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-pulsed dendritic cell vaccine (University of Michigan).